Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Transplant. Sep 18, 2025; 15(3): 102078
Published online Sep 18, 2025. doi: 10.5500/wjt.v15.i3.102078
Table 1 Baseline characteristics in a cohort of extracorporeal membrane oxygenation patients with direct vs consultative primary advanced heart failure and transplant involvement, n (%)

Total (n = 51)
With direct AHFTC role (n = 21)
With consultative AHFTC role (n = 30)
P value
Age (year)47.2 (SD 14.5)47.0 (SD 13.3)47.4 (SD 15.5)0.92
RESP score 3.4 (SD 3.3)3.2 (SD 1.9)3.5 (SD 4.1)0.81
SAVE score-5.7 (SD 3.9)-4.6 (SD 4.3)-6.5 (SD 3.5)0.22
Time on ECMO (days)11.8 (SD 17.3)15.6 (SD 21.8)9.3 (SD 13.3)0.21
Total days of MV prior to cannulation (days)3.6 (SD 5.2)3.0 (SD 3.6)4.0 (SD 6.0)0.51
Renal function2.1 (SD 1.7)1.9 (SD 1.8)2.1 (SD 1.7)0.68
On pressors44 (86)15 (71)29 (97)0.01
Requiring RRT23 (45)5 (24)18 (60)0.01
Requiring mechanical ventilation49 (96)19 (90)30(100)0.09
Requiring tMCS15 (29)5 (24)10 (33)0.46
With Swan-ganz placement20 (39)9 (43)11 (37)0.66
Table 2 Comparison of survival outcomes in a cohort of extracorporeal membrane oxygenation patients with direct vs consultative advanced heart failure and transplant involvement

Total (n = 51)
With direct AHFTC role (n = 21)
With consultative AHFTC role (n = 30)
Unadjusted odds ratio
P value
Adjusted odds ratio1
P value
Total survival after decannulation (%)32/51 (63)15/21 (71)17/30 (57)1.6 (0.5-5.6)0.461.6 (0.4-5.6)0.49
Total survival to 30 days post discharge (%)23/51 (45)14/21 (67)9/30 (30)4.7 (1.4-15)0.015.3 (1.5-19)0.01
VA survival after decannulation (%)17/26 (65)8/11 (73)9/15 (60)2.25 (0.4-14.6)0.402.20 (0.3-16)0.43
VA survival to 30 days post discharge (%)10/26 (38)7/11 (64)3/15 (20)7.0 (1.2-40.8)0.036.4 (1.0-41.7)0.05
VV survival after decannulation. (%)15/25 (60)7/10 (70)8/15 (53)1.7 (0.6-5.9)0.431.8 (0.7-6.1)0.45
VV survival to 30 days post discharge (%)13/25 (52)7/10 (70)6/15 (40)3.5 (0.6-19.2)0.154.8 (0.71-32.2)0.11